Madagascar vs Palau: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Madagascar
0.6%
in 2024
Palau
0.6%
in 2024
Madagascar rank
50th
Palau rank
50th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Madagascar
- Palau
How they compare
Madagascar currently reports 0.6% against 0.6% in Palau, a difference of 0.0%.
Across all 10 years both countries report, Palau has been ahead every year.
Madagascar ranks 50th and Palau ranks 50th of 215 countries.
Palau has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Madagascar | Palau | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.6% | 1.2% | 0.5% | Palau |
| 2020s | 0.5% | 0.7% | 0.1% | Palau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Madagascar or Palau?
- Madagascar, at 0.6% against 0.6% in Palau as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Madagascar and Palau?
- 0.0%, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Palau?
- 10 years are reported by both, from 2015 to 2024.
- How do Madagascar and Palau rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Madagascar ranks 50th and Palau ranks 50th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.